Breast cancer in men in the United States: A population-based study of diagnosis, treatment, and survival

Cancer

Volumn 116, Issue 15, 2010, Pages 3558-3568

  Harlan, Linda C ^a   Zujewski, Jo Anne ^a   Goodman, Marc T ^b   Stevens, Jennifer L ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Breast cancer; Chemotherapy; Diagnosis; Hormones; Men; Radiation; Surgery; Survival; Treatment

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; HEALTH SURVEY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MASTECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; TUMOR VOLUME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS, MALE; HUMANS; MALE; MARITAL STATUS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POPULATION SURVEILLANCE; TAMOXIFEN; UNITED STATES;

EID: 77955395886     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25153     Document Type: Article

References (28)

1. Female Breast Cancer. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Available at: http://seer.cancer.gov/csr/ 1975-2004/results-merged/sect-04-breast.pdf. Accessed April 30, 2010.
2. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, Ga: American Cancer Society; 2009.
3. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678-687.
4. Anderson WF, Devesa SS. Breast cancer in men: a population-based study. Cancer. 2005;104:432-433.
5. Goodman MT, Tung KH, Wilkens LR. Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000. Cancer Causes Control. 2006;17:127-136.
6. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar to different than female breast cancer? Breast Cancer Res Treat. 2004;83:77-86.
7. National Cancer Institute. NCI Physician Desk Query System. Available at: http://www.cancer.gov/cancertopics/ pdq/treatment/malebreast/ HealthProfessional/page3. Accessed April 30, 2010.
8. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. National Comprehensive Cancer Network (NCCN). Available at: http://www.nccn.org/ professionals/ physician-gls/PDF/breast.pdf. Accessed April 30, 2010.
9. Overview of the SEER Program. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Available at: http://seer.cancer. gov/about/. Accessed April 30, 2010.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-383. (Pubitemid 17055592)
11. Green FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
12. Yabroff KR, Harlan LC, Clegg XL, Ballard-Barbash R, Stevens JL, Weaver DL. Is mode of breast cancer detection associated with cancer treatment in the United States? Cancer. 2008;112:1011-1019.
13. Kuerer HM, Albarrain CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27:279-288.
14. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615-1620.
15. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative use and patient outcome in males and females with breast cancer. Ann Oncol. 2005;16:1442-1448.
16. Rusby JE, Smith BL, Dominguez FJ, Golshan M. Sentinel lymph node biopsy in men with breast cancer: a report of 31 consecutive procedures and review of literature. Clin Breast Cancer. 2006;7:406-410.
17. Boughey AC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006;203:475-480.
18. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community based use of chemotherapy and hormonal therapy for early stage breast cancer: 1987-2000. J Clin Oncol. 2006;24:872-877.
19. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999; 96:9212-9217.
20. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
21. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005;97:1262-1271. (Pubitemid 41535367)
22. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486-492.
23. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092. (Pubitemid 38298988)
24. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002;20:3317-3327.
25. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85:2370-2377. (Pubitemid 32269188)
26. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006;20:24:e42-e43.
27. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22:3261-3268.
28. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192-1202.